Skip to Content
Biotechnology and health

Genetically Engineered Immune Cells Are Showing Promise in Fighting HIV

January 3, 2018

CAR-T therapy, a treatment that reprograms DNA of immune cells so they attack disease, has been shown to suppress or even eradicate HIV in lab monkeys.

How it works: As Stat explains, the engineered immune cells seek out and bind to the virus and are also themselves immune to HIV infection, allowing them to keep working.

But: The technique, published in PLoS One, was only tested in lab dishes and two animals. It’s also unclear how long the benefits may last. Given that CAR-T therapies have historically been very expensive, it would likely need to be an out-and-out cure to prove successful.

Backstory: We’ve explained how CAR-T shows huge promise in treating cancer, and many firms are already investing heavily in the hope that the technique will find broader application. That hope, this news suggests, may prove to be founded.

Deep Dive

Biotechnology and health

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

The first gene-editing treatment: 10 Breakthrough Technologies 2024

Sickle-cell disease is the first illness to be beaten by CRISPR, but the new treatment comes with an expected price tag of $2 to $3 million.

We’ve never understood how hunger works. That might be about to change.

Scientists have spent decades trying to unravel the intricate mysteries of the human appetite. Are they on the verge of finally determining how this basic drive functions?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.